WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 15'6601 Infant (under 12 months) mortality rate: 82
GDP / capita (US$): 23'3371 Child (under 5 years) mortality rate: 92

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 2'041  2'050  2'060  2'073  2'091  2'371  2'664  2'513 
Births 23  23  23  23  23  19  36  36 
Surviving infants 22  22  22  22  22  19  35  35 
Pop. less than 5 years 111  110  109  109  109  98  208  173 
Pop. less than 15 years 310  304  299  296  296  423  571  515 
Female 15-49 years 472  480  489  497  506  590  651  646 

Number of reported case

(Click for retrospective incidence data for Latvia)
Diphtheria 13  14  264 
Japanese encephalitis
Measles 36  21 
Mumps 11  15  41  10  1'949 
Pertussis 81  201  257  10  135  129 
Polio*
Rubella 62 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)**
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Latvia)
Vaccine year result method % card seen                                                
BCG          92  94  94  93  92  99* 
DTP1          93  96  92  95  99*  99* 
DTP3          92  94  91  92  92  96 
DTP4          92 
IPV1          93 
HepB_BD          98 
HepB3          92  94  90  89  91  95 
Hib3          92  94  90  91  90  79 
JapEnc         
MCV1          95  96  90  92  95  97 
MCV2          89  92  92  92  93  90 
PCV1          86  88  84  88  64 
PCV3          55  76 
Pol3          92  94  91  92  92  96 
Rota1         
Rota_last         
Rubella1          96  96  90  99  93 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Latvia)
BCG 92  94  94  93  92  99 
DTP1 93  96  92  95  99  99 
DTP3 92  94  91  92  92  96 
HepB3 92  94  90  89  91  95 
HepB_BD 98 
Hib3 92  94  90  91  90  79 
MCV1 95  96  90  92  95  97 
MCV2 89  92  92  92  93  90 
PCV3 87  88  76  76 
Pol3 92  94  91  92  92  96 
Rota_last

Number of districts in the country 119  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 0
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 2-5 days; Yes
DTaPHibHepIPV 2, 4, 6, 12-15 months; Yes
DTaPHibIPV 2, 4, 6 months; Yes risk group
DTaPIPV 7 years; Yes
HPV 12 years (x3); Yes
HepB birth; 1, 2, 12-15 months; Yes for risk newborns or Y14 (x3 doses)
Influenza_Adult >= 65 years; Yes and pregnant women, health care workers and adults with chronic diseases
Influenza_Pediatric 6-23 months; Yes and children with chronic diseases
MMR 12-15 months; 7 years; Yes
MMRV 12-15 months; Yes
Pneumo_conj 2, 4, 12-15 months; Yes
Rotavirus From January 2015
Td Yes adults
TdIPV 14 years; Yes

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  No  Yes  Yes  Yes 
What years does the MYP cover? number 2012-2014  2012-2014  2012-2014    2008-2010     
Nº of districts with microplans that include activities to raise immunization coverage number       NA  NA  NA   

System performance

Total Nº districts in country number 119  119  119  119  33  33  33 
Nº districts with DTP3 coverage >=80% number 27  32  33 
% of districts with DTP3 coverage >=80% From 0 to 100% 82  97  100 
Nº districts with measles (MCV1) coverage >=95% number         17    30 
% of districts with MCV1 coverage >=95% From 0 to 100%       52    91 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  No  No  No     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%   91  100  100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.